{"id":"NCT00662649","sponsor":"Novartis","briefTitle":"Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis","officialTitle":"An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2011-06","completion":"2011-06","firstPosted":"2008-04-21","resultsPosted":"2012-07-12","lastUpdate":"2012-07-12"},"enrollment":920,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fingolimod 0.5 mg","otherNames":["FTY720"]},{"type":"DRUG","name":"Fingolimod 1.25 mg","otherNames":["FTY720"]}],"arms":[{"label":"Fingolimod 1.25 mg","type":"EXPERIMENTAL"},{"label":"Fingolimod 0.5 mg","type":"EXPERIMENTAL"},{"label":"Placebo-fingolimod","type":"EXPERIMENTAL"},{"label":"Placebo-fingolimod 1.25 mg","type":"EXPERIMENTAL"},{"label":"Placebo-fingolimod 0.5 mg","type":"EXPERIMENTAL"}],"summary":"This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to the 24-month Core study (CFTY720D2301/NCT00289978).","primaryOutcome":{"measure":"Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)","timeFrame":"Months 0 to end of study (maximum up to 60 months)","effectByArm":[{"arm":"Fingolimod 1.25 mg","deltaMin":0.164,"sd":null},{"arm":"Fingolimod 0.5 mg","deltaMin":0.185,"sd":null},{"arm":"Placebo-fingolimod","deltaMin":0.357,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":103,"countries":["Australia","Belgium","Canada","Czechia","Estonia","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Netherlands","Poland","Romania","Russia","Slovakia","South Africa","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.msclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":289},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Lymphopenia","Headache","Influenza"]}}